Astellas Reports Submission of sNDA to MHLW for Evrenzo (roxadustat) to Treat Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
Shots:
- The sNDA is based on three studies in 500+ patients with NDD-CKD. The first P-III study involve assessing Evrenzo vs darbepoetin alfa resulted in meeting 1EPs of non-inferiority and maintenance of Hb levels over time and is well tolerated
- The other two studies (one P-II & one P-III) supported the safety and efficacy in patients naïve to erythropoiesis-stimulating agents (ESAs)
- Roxadustat is first-in-class- hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and has received MHLW’s approval to treat anemia associated with DD-CKD in Sept’2019 and launched in Nov’19
Click here to read full press release/ article | Ref: Astellas | Image: Astellas
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com